Acteoside attenuates TSLP-induced mast cell proliferation via down-regulating MDM2

Area of Science:

• Immunology
• Pharmacology
• Cell Biology

Background:

• Thymic stromal lymphopoietin (TSLP) drives inflammatory diseases by promoting mast cell proliferation via MDM2 activation.
• Mast cells are key players in inflammatory responses, and their proliferation is a therapeutic target.

Purpose of the Study:

• To investigate the effect of acteoside on MDM2 expression in TSLP-stimulated human mast cells (HMC-1).
• To explore acteoside's potential in modulating inflammatory pathways mediated by mast cells.

Main Methods:

• Human mast cell line (HMC-1) stimulation with TSLP.
• Treatment with acteoside to assess effects on MDM2, p53, STAT signaling, cytokine levels, and apoptosis markers.
• Analysis of mRNA expression for TSLP and IL-7 receptors.

Main Results:

• Acteoside down-regulated TSLP-induced MDM2 upregulation and p53 downregulation.
• Acteoside decreased phosphorylation of STAT6 and STAT5, and reduced levels of IL-13, IL-6, TNF-α, and IL-1β.
• Acteoside induced apoptosis by activating caspase-3 and reducing Bcl2, while also decreasing TSLP and IL-7 receptor mRNA.

Conclusions:

• Acteoside specifically regulates MDM2 activation in TSLP-stimulated mast cells.
• Acteoside exhibits anti-inflammatory and pro-apoptotic effects in mast cells.
• Acteoside shows potential for treating mast cell-mediated inflammatory diseases.